Valuation : Morepen Laboratories Limited

Market Cap 18.52B 196M 168M 158M 145M 270M 271M 1.88B 726M 9.48B 735M 719M 30.21B P/E 2024
22.4x
P/E 2025 21.8x
Enterprise Value 18.52B 196M 168M 158M 145M 270M 271M 1.88B 726M 9.48B 735M 719M 30.21B EV / Sales 2024
1.27x
EV / Sales 2025 1.45x
Free-Float
57.31%
Yield 2024 *
-
Yield 2025 0.42%
1 day+4.35%
1 week+11.71%
Current month+10.77%
1 month+49.28%
3 months+171.01%
6 months+198.04%
Current year+188.90%
1 week 100.25
Extreme 100.25
122.05
1 month 73
Extreme 73
122.05
Current year 33.44
Extreme 33.44
122.05
1 year 33.44
Extreme 33.44
122.05
3 years 31.31
Extreme 31.31
122.05
5 years 23.65
Extreme 23.65
122.05
10 years 7.21
Extreme 7.21
122.05
Manager TitleAgeSince
Chief Executive Officer 58 30/06/2026
Chief Executive Officer 62 31/01/1992
Director of Finance/CFO 59 02/04/2002
Director TitleAgeSince
Chairman 62 31/01/1992
Director/Board Member 58 12/08/2019
Director/Board Member - 21/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+11.71%+140.62%+197.44% 660M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.95%-1.42%+28.96%+40.10% 352B
-3.18%+1.39%+20.66%+43.86% 304B
+0.30%+0.60%-0.40%+13.54% 252B
-1.55%+1.11%+54.15%+75.59% 236B
+0.02%+1.17%-14.59%-54.96% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.46%+1.84%+39.36%+67.45% 367.9B
Weighted average by Cap. -1.07%+0.62%+37.22%+67.54%

Financials

2024 2025
Net sales 17.02B 180M 155M 146M 133M 249M 249M 1.73B 667M 8.72B 676M 661M 27.76B 18.12B 192M 165M 155M 141M 265M 265M 1.84B 710M 9.28B 719M 704M 29.55B
Net income 962M 10.17M 8.74M 8.22M 7.51M 14.04M 14.09M 97.51M 37.69M 492M 38.18M 37.35M 1.57B 1.18B 12.48M 10.73M 10.09M 9.21M 17.23M 17.29M 120M 46.26M 604M 46.86M 45.84M 1.93B
Net Debt 121M 1.27M 1.1M 1.03M 941K 1.76M 1.77M 12.22M 4.72M 61.73M 4.79M 4.68M 197M -928K -9.81K -8.44K -7.94K -7.25K -13.55K -13.59K -94.11K -36.38K -475K -36.85K -36.04K -1.51M
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,814
Date Price Change Volume
07/09/26 ₹118.65 +4.35% 1,401,707
04/09/26 ₹113.70 -3.15% 908,355
03/09/26 ₹117.40 +3.99% 1,842,486
02/09/26 ₹112.90 +8.77% 2,261,394
01/09/26 ₹103.80 -3.09% 1,353,302
  1. Stock Market
  2. Stocks
  3. MOREPENLAB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!